HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX ® B/E

Vaccine

Volumn 30, Issue 5, 2012, Pages 832-836

  Paris, Robert ^a   Bejrachandra, Sasitorn ^b   Thongcharoen, Prasert ^b   Nitayaphan, Sorachai ^a   Pitisuttithum, Punnee ^e   Sambor, Anna ^c   Gurunathan, Sanjay ^d   Francis, Donald ^e   Ratto Kim, Silvia ^f   Karnasuta, Chitraporn ^d   de Souza, Mark S ^a   Polonis, Victoria R ^a   Brown, Arthur E ^d   Kim, Jerome H ^g   Stephens, Henry A ^h  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Henry M Jackson Foundation and US Military HIV Research Program   (United States)

^e SANOFI PASTEUR   (France)

^f Global Solutions for Infectious Diseases   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

HIV 1; HLA; MHC; Neutralizing antibody; RV135; RV144; Vaccine

Indexed keywords

ALVAC HIV; HETERODIMER; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR2 ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB5 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ALLELE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLADISTICS; CLINICAL ARTICLE; ETHNICITY; GENE FREQUENCY; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; THAILAND; TREATMENT RESPONSE; VACCINATION;

AIDS VACCINES; ALLELES; ANTIBODIES, NEUTRALIZING; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV ANTIBODIES; HUMAN EXPERIMENTATION; HUMANS; THAILAND;

EID: 84855439087     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.002     Document Type: Article

References (30)

1. Taylor B.S., Sobieszczyk M.E., McCutchan F.E., Hammer S.M. The challenge of HIV-1 subtype diversity. N Engl J Med 2008, 358(April (15)):1590-1602.
2. Stephens H.A. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol 2005, 26(January (1)):41-47.
3. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
4. Paris R., Bejrachandra S., Karnasuta C., Chandanayingyong D., Kunachiwa W., Leetrakool N., et al. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens 2004, 64(3):251-256.
5. Delves P.J., Roitt I.M. The immune system - second of two parts. N Engl J Med 2000, 343(July (2)):108-117.
6. Wang P., Sidney J., Kim Y., Sette A., Lund O., Nielsen M., et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010, 11:568.
7. Chandanayingyong D., Udee S., Klaythong R., Sirikong M., Rungroung E., Chantangpol R., et al. HLA haplotype frequencies in Thais. Southeast Asian J Trop Med Public Health 1995, 26(Suppl. 1):301-305.
8. Chandanayingyong D., Stephens H.A., Klaythong R., Sirikong M., Udee S., Longta P., et al. HLA-A, -B, -DRB1 -DQA1, and -DQB1 polymorphism in Thais. Hum Immunol 1997, 53(2):174-182.
9. Stephens H.A., Chandanayingyong D., Kunachiwa W., Sirikong M., Longta K., Maneemaroj R., et al. A comparison of molecular HLA-DR and DQ allele profiles forming DR51-, DR52-, and DR53-related haplotypes in five ethnic Thai populations from mainland southeast Asia. Hum Immunol 2000, 61(10):1039-1047.
10. Stephens H.A., Brown A.E., Chandanayingyong D., Webster H.K., Sirikong M., Longta P., et al. The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen. EurJ Immunol 1995, 25(11):3142-3147.
11. Nitayaphan S., Pitisuttithum P., Karnasuta C., Eamsila C., de Souza M., Morgan P., et al. Safety and Immunogenicity of an HIV Subtype B and E Prime-Boost Vaccine Combination in HIV-Negative Thai Adults. J Infect Dis 2004, 190(4):702-706.
12. Pitisuttithum P., Nitayaphan S., Thongcharoen P., Khamboonruang C., Kim J., de Souza M., et al. Safety and Immunogenicity of Combinations of Recombinant Subtype E and B Human Immunodeficiency Virus Type 1 Envelope Glycoprotein 120 Vaccines in Healthy Thai Adults. J Infect Dis 2003, 188(2):219-227.
13. Kim J.H., Pitisuttithum P., Kamboonruang C., Chuenchitra T., Mascola J., Frankel S.S., et al. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res Hum Retroviruses 2003, 19(9):807-816.
14. Fernandez-Vina M., Bignon J.D. Primers and oligonucleotides probes (SSOP) used for DNA typing of HLA class II aleles. Genetic diversity of HLA: functional and medical implications 1996, 596-632. EDK, France. D. Charron (Ed.).
15. Hosmer D.W., Lemeshow S. Applied logistic regression 1989, John Wiley and Sons, Toronto.
16. Pitisuttithum P., Berman P.W., Phonrat B., Suntharasamai P., Raktham S., Srisuwanvilai L.O., et al. Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1. J Acquir Immune Defic Syndr 2004, 37(1):1160-1165.
17. Gilbert P., Wang M., Wrin T., Petropoulos C., Gurwith M., Sinangil F., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010, 202(4):595-605.
18. Erlich H., Valdes A.M., Noble J., Carlson J.A., Varney M., Concannon P., et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57(4):1084-1092.
19. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I., Walker B.D., et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330(6010):1551-1557.
20. Kruskall M.S., Alper C.A., Awdeh Z., Yunis E.J., Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Exp Med 1992, 175(February (2)):495-502.
21. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Shane P.V., Jacobsen S.J., Poland G.A. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 2004, 22(May (15-16)):1914-1920.
22. Gelder C.M., Lambkin R., Hart K.W., Fleming D., Williams O.M., Bunce M., et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002, 185(1):114-117.
23. Todd J.A., Bell J.I., McDevitt H.O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987, 329(October (6140)):599-604.
24. Khalil I., d'Auriol L., Gobet M., Morin L., Lepage V., Deschamps I., et al. A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest 1990, 85(April (4)):1315-1319.
25. Caillat-Zucman S. Molecular mechanisms of HLA association with autoimmune diseases. Tissue Antigens 2009, 73(January (1)):1-8.
26. Kwok W.W., Nepom G.T., Raymond F.C. HLA-DQ polymorphisms are highly selective for peptide binding interactions. J Immunol 1995, 155(September (5)):2468-2476.
27. Hovhannisyan Z., Weiss A., Martin A., Wiesner M., Tollefsen S., Yoshida K., et al. The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 2008, 456(Nov (7221)):534-538.
28. Norris P.J., Moffett H.F., Brander C., Allen T.M., O'Sullivan K.M., Cosimi L.A., et al. Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res Hum Retrovirusess 2004, 20(3):315-325.
29. Khalil-Daher I., Boisgerault F., Feugeas J.P., Tieng V., Toubert A., Charron D. Naturally processed peptides from HLA-DQ7 (alpha1*0501-beta1*0301): influence of both alpha and beta chain polymorphism in the HLA-DQ peptide binding specificity. Eur J Immunol 1998, 28(November (11)):3840-3849.
30. Nielsen M., Lund O., Buus S., Lundegaard C. MHC class II epitope predictive algorithms. Immunology 2010, 130(July (3)):319-328.